SGIOF
Shionogi & Co., Ltd.
Price Chart
Latest Quote
$16.00
+0.00 (+0.00%)
Current Price
| Previous Close | $16.00 |
| Open | $19.00 |
| Day High | $19.00 |
| Day Low | $17.68 |
| Volume | 500 |
Stock Information
Note: Financial values converted from JPY to USD
| Quarterly Dividend / Yield | $0.48 / 3.03% |
| Shares Outstanding | 850.98M |
| Quarterly Dividend Yield | 3.03% |
| Quarterly Dividend | $0.48 |
| Total Debt | $4.27B |
| Cash Equivalents | $4.44B |
| Revenue | $3.12B |
| Net Income | $1.28B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $13.62B |
| P/E Ratio | 10.67 |
| EPS (TTM) | $1.50 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-12.40B |
| Sales | $3.12B |
| Income | $1.28B |
| Book/sh | $12.46 |
| Cash/sh | $835.98 |
Financial Ratios
| Quick Ratio | 1.05 |
| Current Ratio | 1.58 |
| Debt/Eq | 40.59 |
| EPS Growth TTM | 28.20% |
Returns & Margins
| ROA | 3.78% |
| ROE | 13.51% |
| Gross Margin | 83.50% |
| Operating Margin | -18.60% |
| Profit Margin | 41.06% |
Ownership
| Insider Ownership | 4.83% |
| Institutional Ownership | 60.40% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 12.90 |
| P/S | 0.03 |
| P/B | 1.28 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $17.37 |
| SMA50 | $18.78 |
| SMA200 | $18.41 |
| ATR | 0.2059 |
| Shares Float | 850.98M |
| Volatility | 0.03 |
Performance History
| Week | +0.00% |
| Month | -9.50% |
| Quarter | -31.59% |
| 6 Months | +6.29% |
| YTD | +6.29% |
| Year | +7.61% |
| 3 Years | +17.83% |
| 5 Years | +5.54% |
| 10 Years | +3.75% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-15 | $16.00 | 0 |
| 2026-06-12 | $16.00 | 0 |
| 2026-06-11 | $16.00 | 0 |
| 2026-06-10 | $16.00 | 0 |
| 2026-06-09 | $16.00 | 0 |
| 2026-06-08 | $16.00 | 0 |
| 2026-06-05 | $16.00 | 0 |
| 2026-06-04 | $16.00 | 200 |
| 2026-06-03 | $17.68 | 1,000 |
| 2026-06-02 | $18.88 | 0 |
| 2026-06-01 | $18.88 | 0 |
| 2026-05-29 | $18.88 | 0 |
| 2026-05-28 | $18.88 | 0 |
| 2026-05-27 | $18.88 | 0 |
| 2026-05-26 | $18.88 | 1,500 |
| 2026-05-22 | $17.68 | 0 |
| 2026-05-21 | $17.68 | 0 |
| 2026-05-20 | $17.68 | 0 |
| 2026-05-19 | $17.68 | 0 |
| 2026-05-18 | $17.68 | 600 |
About Shionogi & Co., Ltd.
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.
đ° Latest News
Shionogi (TSE:4507) Valuation Check As XOCOVA Wins First US FDA Approval For COVID 19 Post Exposure Prophylaxis
Simply Wall St. âĸ 2026-06-10T20:06:59Z
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T12:50:07Z
D-Wave CEO on quantum computing's ChatGPT moment, Nvidia, & more
Yahoo Finance Video âĸ 2026-04-14T15:23:50Z
Shionogiâs Fetroja Contract And Data Shift U.S. Growth And Valuation Outlook
Simply Wall St. âĸ 2026-04-13T00:21:27Z
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders
BioPharma Dive âĸ 2026-04-10T11:10:07Z
Shionogi secures $482m BARDA contract to tackle AMR crisis
Pharmaceutical Technology âĸ 2026-04-09T10:06:58Z
A Look At Shionogi (TSE:4507) Valuation After Recent Share Price Momentum
Simply Wall St. âĸ 2026-03-27T03:10:52Z
SGIOY vs. SDZNY: Which Stock Is the Better Value Option?
Zacks âĸ 2026-03-26T15:40:03Z
Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease
MarketBeat âĸ 2026-03-25T19:09:14Z
SGIOY or SDZNY: Which Is the Better Value Stock Right Now?
Zacks âĸ 2026-02-19T16:40:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $406,253,001 | $366,637,191 | $396,196,288 | $352,716,918 |
| Cost Of Revenue | $406,253,001 | $366,637,191 | $396,196,288 | $352,716,918 |
| Total Revenue | $2,789,579,326 | $2,769,294,046 | $2,715,847,073 | $2,133,156,051 |
| Operating Revenue | $2,789,579,326 | $2,769,294,046 | $2,715,847,073 | $2,133,156,051 |
| Expenses | ||||
| Interest Expense | $57,456,927 | $42,651,919 | $28,642,536 | $5,352,972 |
| Total Expenses | $1,792,787,248 | $1,793,461,939 | $1,767,429,056 | $1,431,012,924 |
| Net Non Operating Interest Income Expense | $280,996,008 | $286,253,505 | $454,009,656 | $101,560,068 |
| Interest Expense Non Operating | $57,456,927 | $42,651,919 | $28,642,536 | $5,352,972 |
| Operating Expense | $1,386,534,248 | $1,426,824,748 | $1,371,232,768 | $1,078,296,005 |
| Other Operating Expenses | $23,563,260 | $154,937,025 | $98,307,549 | $28,967,151 |
| General And Administrative Expense | $648,422,460 | $634,279,412 | $622,338,657 | $584,123,149 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,084,820,138 | $1,031,322,246 | $1,177,303,705 | $726,788,438 |
| Net Interest Income | $280,996,008 | $286,253,505 | $454,009,656 | $101,560,068 |
| Interest Income | $338,452,935 | $328,905,423 | $482,652,192 | $106,913,039 |
| Normalized Income | $1,084,820,138 | $1,031,322,246 | $1,177,303,705 | $726,788,438 |
| Net Income From Continuing And Discontinued Operation | $1,084,820,138 | $1,031,322,246 | $1,177,303,705 | $726,788,438 |
| Total Operating Income As Reported | $996,779,348 | $975,819,376 | $948,405,287 | $702,136,762 |
| Net Income Common Stockholders | $1,084,820,138 | $1,031,322,246 | $1,177,303,705 | $726,788,438 |
| Net Income | $1,084,820,138 | $1,031,322,246 | $1,177,303,705 | $726,788,438 |
| Net Income Including Noncontrolling Interests | $1,079,085,266 | $1,022,061,160 | $1,174,318,516 | $722,040,143 |
| Net Income Continuous Operations | $1,079,091,631 | $1,022,061,160 | $1,174,318,516 | $722,040,143 |
| Pretax Income | $1,277,775,356 | $1,262,072,881 | $1,402,414,943 | $803,696,830 |
| Interest Income Non Operating | $338,452,935 | $328,905,423 | $482,652,192 | $106,913,039 |
| Operating Income | $996,785,713 | $975,832,106 | $948,411,652 | $702,136,762 |
| Depreciation And Amortization In Income Statement | $26,593,003 | $23,728,750 | $23,677,830 | $22,124,768 |
| Depreciation Income Statement | $0 | $0 | $0 | $0 |
| Gross Profit | $2,383,319,961 | $2,402,656,855 | $2,319,644,420 | $1,780,432,768 |
| Per Share | ||||
| Diluted EPS | $1.27 | $1.18 | $1.32 | $0.80 |
| Basic EPS | $1.28 | $1.18 | $1.32 | $0.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,468,470,996 | $1,421,350,841 | $1,540,312,841 | $913,124,048 |
| Reconciled Depreciation | $133,238,712 | $116,626,042 | $109,255,362 | $104,074,246 |
| EBITDA (Bullshit earnings) | $1,468,470,996 | $1,421,350,841 | $1,540,312,841 | $913,124,048 |
| EBIT | $1,335,232,283 | $1,304,724,800 | $1,431,057,479 | $809,049,802 |
| Diluted Average Shares | $5,416,214 | $5,541,599 | $5,686,542 | $5,758,658 |
| Basic Average Shares | $5,414,299 | $5,539,677 | $5,684,620 | $5,756,730 |
| Diluted NI Availto Com Stockholders | $1,084,820,138 | $1,031,322,246 | $1,177,303,705 | $726,788,438 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Minority Interests | $5,728,507 | $9,261,087 | $2,985,189 | $4,748,296 |
| Tax Provision | $198,683,725 | $240,011,722 | $228,096,427 | $81,656,688 |
| Amortization | $26,593,003 | $23,728,750 | $23,677,830 | $22,124,768 |
| Research And Development | $691,316,249 | $653,304,421 | $651,725,899 | $464,620,124 |
| Selling General And Administration | $648,422,460 | $634,279,412 | $622,338,657 | $584,123,149 |
Fetched: 2026-02-06
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $7,654,318,151 | $7,017,116,043 | $6,326,497,091 | $5,631,938,073 |
| Total Assets | $9,772,819,269 | $9,018,981,048 | $8,349,882,872 | $7,323,817,336 |
| Total Non Current Assets | $4,308,254,400 | $4,027,344,939 | $3,358,329,511 | $3,127,838,881 |
| Other Non Current Assets | $266,524,086 | $268,376,362 | $42,767,848 | $38,573,174 |
| Non Current Deferred Taxes Assets | $84,300,845 | $86,095,835 | $140,671,148 | $82,155,769 |
| Investmentin Financial Assets | $1,908,283,683 | $1,860,684,640 | $1,576,732,609 | $1,543,429,828 |
| Goodwill And Other Intangible Assets | $1,014,614,522 | $845,987,371 | $675,527,039 | $578,349,373 |
| Other Intangible Assets | $914,375,190 | $748,682,401 | $613,027,039 | $517,001,476 |
| Current Assets | $5,464,558,503 | $4,991,629,743 | $4,991,546,996 | $4,195,978,456 |
| Other Current Assets | $176,029,891 | $143,904,674 | $338,272,736 | $159,894,083 |
| Inventory | $416,774,875 | $413,203,992 | $368,666,615 | $292,112,231 |
| Accounts Receivable | $767,345,197 | $781,838,781 | $698,734,595 | $782,698,085 |
| Cash Cash Equivalents And Short Term Investments | $4,104,408,540 | $3,652,682,296 | $3,585,873,049 | $2,960,949,432 |
| Cash And Cash Equivalents | $2,385,648,994 | $2,279,318,156 | $1,968,275,790 | $1,619,436,805 |
| Taxes Receivable | - | - | $432,834 | $324,626 |
| Debt | ||||
| Total Debt | $139,283,532 | $73,963,744 | $59,902,994 | $42,481,414 |
| Long Term Debt And Capital Lease Obligation | $117,234,443 | $55,714,686 | $40,718,250 | $23,735,869 |
| Current Debt And Capital Lease Obligation | $22,049,088 | $18,249,058 | $19,184,744 | $18,745,544 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,100,245,696 | $1,046,166,869 | $1,208,893,471 | $1,001,349,424 |
| Total Non Current Liabilities Net Minority Interest | $276,638,405 | $193,820,654 | $199,676,647 | $209,542,723 |
| Other Non Current Liabilities | $27,790,508 | $10,782,666 | $8,567,573 | $2,266,015 |
| Non Current Deferred Taxes Liabilities | $28,013,291 | $27,752,317 | $37,656,584 | $49,693,197 |
| Current Liabilities | $823,607,291 | $852,346,216 | $1,009,216,823 | $791,806,700 |
| Other Current Liabilities | $457,397,647 | $409,092,066 | $442,993,176 | $414,241,521 |
| Payables | $229,007,536 | $226,932,478 | $357,864,853 | $218,613,148 |
| Total Tax Payable | $142,574,346 | $132,676,443 | $268,720,083 | $114,401,925 |
| Accounts Payable | $86,433,191 | $94,256,034 | $89,144,770 | $104,211,223 |
| Equity | ||||
| Common Stock Equity | $8,668,932,673 | $7,863,103,414 | $7,002,024,130 | $6,210,287,447 |
| Total Equity Gross Minority Interest | $8,672,573,573 | $7,972,814,179 | $7,140,989,401 | $6,322,467,913 |
| Stockholders Equity | $8,668,932,673 | $7,863,103,414 | $7,002,024,130 | $6,210,287,447 |
| Other Equity Interest | $1,737,231,386 | $1,729,936,855 | $1,184,126,437 | $1,049,152,153 |
| Retained Earnings | $7,101,849,723 | $6,784,760,407 | $5,987,154,999 | $5,301,952,841 |
| Other | ||||
| Treasury Shares Number | $247,892 | $456,282 | $249,776 | $192,931 |
| Ordinary Shares Number | $5,414,804 | $5,413,451 | $5,619,957 | $5,757,004 |
| Share Issued | $5,662,696 | $5,869,733 | $5,869,733 | $5,949,934 |
| Tangible Book Value | $7,654,318,151 | $7,017,116,043 | $6,326,497,091 | $5,631,938,073 |
| Invested Capital | $8,668,932,673 | $7,863,103,414 | $7,002,024,130 | $6,210,287,447 |
| Working Capital | $4,640,951,212 | $4,139,283,528 | $3,982,330,172 | $3,404,171,755 |
| Capital Lease Obligations | $139,283,532 | $73,963,744 | $59,902,994 | $42,481,414 |
| Total Capitalization | $8,668,932,673 | $7,863,103,414 | $7,002,024,130 | $6,210,287,447 |
| Minority Interest | $3,640,900 | $109,710,765 | $138,965,271 | $112,180,466 |
| Treasury Stock | $419,180,924 | $877,692,483 | $401,479,274 | $368,271,972 |
| Additional Paid In Capital | $113,587,178 | $90,653,325 | $96,776,657 | $92,009,115 |
| Capital Stock | $135,445,310 | $135,445,310 | $135,445,310 | $135,445,310 |
| Common Stock | $135,445,310 | $135,445,310 | $135,445,310 | $135,445,310 |
| Non Current Pension And Other Postretirement Benefit Plans | $51,036,256 | $50,883,491 | $81,901,161 | $98,100,621 |
| Long Term Capital Lease Obligation | $117,234,443 | $55,714,686 | $40,718,250 | $23,735,869 |
| Current Capital Lease Obligation | $22,049,088 | $18,249,058 | $19,184,744 | $18,745,544 |
| Available For Sale Securities | $1,908,283,683 | $1,860,684,640 | $1,576,732,609 | $1,543,429,828 |
| Investment Properties | $176,456,360 | $176,749,160 | $167,926,978 | $169,772,889 |
| Goodwill | $100,239,332 | $97,304,970 | $62,500,000 | $61,347,897 |
| Net PPE | $858,074,905 | $789,451,573 | $754,703,890 | $715,557,846 |
| Gross PPE | $858,074,905 | $789,451,573 | $754,703,890 | $715,557,846 |
| Other Properties | $858,074,905 | $789,451,573 | $754,703,890 | $715,557,846 |
| Other Short Term Investments | $1,718,759,546 | $1,373,364,140 | $1,617,597,259 | $1,341,512,627 |
Fetched: 2026-02-06
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $912,497,453 | $802,124,706 | $895,457,785 | $448,772,787 |
| Operating Activities | ||||
| Operating Cash Flow | $1,244,144,005 | $982,050,106 | $1,132,160,860 | $649,684,285 |
| Investing Activities | ||||
| Capital Expenditure | $-331,646,552 | $-179,925,400 | $-236,703,075 | $-200,911,498 |
| Investing Cash Flow | $-738,873,612 | $37,694,775 | $-307,388,736 | $-612,358,692 |
| Net Other Investing Changes | $-11,794,735 | $-18,217,232 | $21,043,385 | $5,983,298 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-63,652 | $-478,549,241 | $-315,326,153 | $-89,113 |
| Financing Cash Flow | $-413,153,070 | $-807,446,022 | $-535,460,586 | $-233,062,175 |
| Net Other Financing Charges | $-82,684,082 | $-30,011,967 | $30,018,332 | $-12,730 |
| Cash Dividends Paid | $-309,973,011 | $-279,279,967 | $-230,051,431 | $-210,981,261 |
| Common Stock Dividend Paid | $-309,973,011 | $-279,279,967 | $-230,051,431 | $-210,981,261 |
| Net Common Stock Issuance | $-63,652 | $-478,549,241 | $-315,326,153 | $-89,113 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $2,385,648,994 | $2,279,318,156 | $1,968,275,790 | $1,619,436,805 |
| Beginning Cash Position | $2,279,318,156 | $1,968,275,790 | $1,619,436,805 | $1,757,899,224 |
| Effect Of Exchange Rate Changes | $14,213,515 | $98,737,142 | $59,527,447 | $57,274,162 |
| Changes In Cash | $92,117,323 | $212,298,859 | $289,311,539 | $-195,736,582 |
| Common Stock Payments | $-63,652 | $-478,549,241 | $-315,326,153 | $-89,113 |
| Net Investment Purchase And Sale | $-386,998,421 | $410,855,229 | $-91,729,046 | $-417,430,491 |
| Sale Of Investment | $2,404,146,296 | $2,223,947,192 | $2,978,008,195 | $2,127,227,821 |
| Purchase Of Investment | $-2,791,144,717 | $-1,813,091,963 | $-3,069,737,241 | $-2,544,658,313 |
| Net Business Purchase And Sale | $-8,433,904 | $-175,017,822 | $0 | $0 |
| Purchase Of Business | $-8,433,904 | $-175,017,822 | $0 | $0 |
| Net Intangibles Purchase And Sale | $-222,635,961 | $-99,131,785 | $-161,224,412 | $-34,238,466 |
| Purchase Of Intangibles | $-222,635,961 | $-99,131,785 | $-161,224,412 | $-34,238,466 |
| Net PPE Purchase And Sale | $-109,010,592 | $-80,793,614 | $-75,478,664 | $-166,673,032 |
| Purchase Of PPE | $-109,010,592 | $-80,793,614 | $-75,478,664 | $-166,673,032 |
| Taxes Refund Paid | $-202,521,896 | $-405,062,888 | $-173,668,398 | $-165,737,346 |
| Interest Received Cfo | $332,200,326 | $313,957,633 | $316,452,795 | $157,901,772 |
| Interest Paid Cfo | $-1,941,389 | $-1,043,894 | $-598,330 | $-553,773 |
| Change In Working Capital | $-1,152,103 | $-156,113,148 | $63,524,799 | $-247,377,533 |
| Change In Payable | $-10,839,953 | $-37,026,428 | $49,253,997 | $74,383,848 |
| Change In Inventory | $-2,469,702 | $-40,336,338 | $-74,466,595 | $-45,403,045 |
| Change In Receivables | $12,157,552 | $-78,750,382 | $88,737,397 | $-276,358,336 |
| Other Non Cash Items | $-295,110,245 | $-201,013,341 | $-660,110,499 | $-3,246,257 |
| Depreciation And Amortization | $133,242,947 | $116,629,748 | $109,258,835 | $104,077,554 |
| Depreciation | $133,242,947 | $116,629,748 | $109,258,835 | $104,077,554 |
| Net Income From Continuing Operations | $1,277,815,968 | $1,262,112,994 | $1,402,459,516 | $803,722,374 |
| Other Cash Adjustment Outside Changein Cash | - | $6,365 | - | - |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-02-06